Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Open Access
- 24 May 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (6), 2447-2463
- https://doi.org/10.1172/jci64859
Abstract
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.This publication has 60 references indexed in Scilit:
- Interleukin-12 Converts Foxp3+ Regulatory T Cells to Interferon–γ-Producing Foxp3+ T Cells That Inhibit ColitisGastroenterology, 2011
- Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune diseaseNature Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)Annual Review of Immunology, 2010
- Interleukin 12 Stimulates IFN-γ–Mediated Inhibition of Tumor-Induced Regulatory T-Cell Proliferation and Enhances Tumor ClearanceCancer Research, 2009
- Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient OutcomeCancer Research, 2009
- T-regulatory cell modulation: the future of cancer immunotherapy?British Journal of Cancer, 2009
- Cancer Immunotherapy — The Endgame BeginsThe New England Journal of Medicine, 2008
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006